--- title: "Pre-market hot trades in US stocks: Biovie pre-market down 10.65%; T1 Energy pre-market down 8.72%" type: "News" locale: "en" url: "https://longbridge.com/en/news/288554736.md" description: "Biovie pre-market down 10.65%; T1 Energy pre-market down 8.72%; Xos pre-market up 232.74%; Wellchange pre-market up 111.96%; J-Star pre-market up 56.08%" datetime: "2026-06-03T10:02:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288554736.md) - [en](https://longbridge.com/en/news/288554736.md) - [zh-HK](https://longbridge.com/zh-HK/news/288554736.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Biovie pre-market down 10.65%; T1 Energy pre-market down 8.72% **Pre-market Hot Trades in US Stocks** Biovie is down 10.65% in pre-market trading. Based on recent key news: 1. On June 2, BioVie Inc. released research results regarding its main assets bezisterim and BIV201, showing strong signals in Parkinson's disease, Alzheimer's disease, long COVID, and ascites. Despite the positive results, the market remains cautious about the upcoming clinical trial results, leading to a decline in stock price. 2. On June 3, BioVie Inc. announced that the results of two major clinical trials for Parkinson's disease and long COVID, which are to be announced soon, show good safety and early efficacy signals. However, the uncertainty surrounding these results has increased investor concerns, further depressing the stock price. 3. On June 1, the research progress mentioned in the original documents released by BioVie Inc. failed to fully alleviate market doubts about its future profitability, leading to a lack of investor confidence and pressure on the stock price. The biotechnology industry has been highly volatile recently, and investors should exercise caution. T1 Energy is down 8.72% in pre-market trading. Based on recent key news: 1. On June 1, T1 Energy raised over $440 million in the fourth quarter, began construction on the G2 project, and signed a series of contracts to maintain 45x compliance. While these initiatives established a solid financial foundation, the implementation of new OBBBA restrictions has resulted in a one-time impact on EBITDA for 2025, with net sales falling short of expectations by $16 million, causing the stock price to drop. 2. On June 1, T1 Energy invested a significant amount of cash in the critical phase of G2\_Austin, reducing the remaining capital needed to complete the first phase. Although these investments support long-term growth, they have put pressure on the financial situation in the short term, leading to a decline in stock price. 3. On June 1, T1 Energy received a $34 million sales commission waiver, but due to accounting standards restrictions, this favorable cash impact could not be recognized in the income statement, further exacerbating market concerns about its financial performance and leading to a drop in stock price. Recent industry policy changes have had a significant impact. **Top Gainers in Pre-market US Stocks** Xos is up 232.74% in pre-market trading. Based on recent key news: 1. On June 3, Xos launched a 2.5MWh power hub, providing off-grid energy storage solutions. This innovation allows data centers to rapidly deploy energy storage within days, significantly shortening the implementation time that typically takes years, driving a substantial increase in stock price. Source: Xos, Inc. 2. On June 3, Benzinga's stock rankings indicate that XOS is undergoing long-term consolidation while showing an upward trend in the short and medium term. This improvement in market sentiment further supports the rise in stock price. Source: Benzinga On June 2nd, Xos announced that its 2.5MWh power hub will be manufactured at its production facility in Tennessee, showcasing its capability in deploying AI data center facilities and enhancing market confidence in its technology. Source: Xos, Inc. U.S. stocks hit all-time highs, and market sentiment is positive. Wellchange pre-market rose 111.96%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. J-Star pre-market rose 56.08%. Based on recent key news: 1. On June 1st, J-Star Holding announced it signed a letter of intent with the Baytown Economic Development Foundation to support the construction of a solid-state battery manufacturing facility in the U.S. This move is seen as an important layout for the company in the new energy sector, driving a significant increase in stock price. Source: YMAT Stock News 2. On June 2nd, J-Star received authorization from the Central Bank of Taiwan to seek $60 million in financing for its YMA division to build a $122.5 million solid-state battery plant in Baytown, Texas. This news has strengthened market confidence in the company's future growth. Source: GlobeNewswire 3. On June 3rd, J-Star's application for funding from the U.S. Department of Energy is still under review, demonstrating the company's ongoing investment and potential support in the new energy sector, further boosting investor sentiment. Source: GlobeNewswire The investment boom in the new energy industry continues, with enhanced policy support ### Related Stocks - [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md) - [TE.US](https://longbridge.com/en/quote/TE.US.md) - [XOS.US](https://longbridge.com/en/quote/XOS.US.md) - [WCT.US](https://longbridge.com/en/quote/WCT.US.md) - [YMAT.US](https://longbridge.com/en/quote/YMAT.US.md) ## Related News & Research - [Why Is T1 Energy Stock Sinking Tuesday?](https://longbridge.com/en/news/281197983.md) - [BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration](https://longbridge.com/en/news/295718009.md) - [BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3](https://longbridge.com/en/news/295701512.md) - [BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease](https://longbridge.com/en/news/295101020.md) - [BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease](https://longbridge.com/en/news/295220567.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**